Get informed when a big investor buys or sells
+ FollowLoading insider trades…
Loading congress trades…
| Market cap | $2.19 Billion |
|---|---|
| Enterprise Value | $2.09 Billion |
| Earnings per Share | $4.87 |
| Beta | 0.12 |
| Outstanding Shares | 65,655,167 |
| P/E Ratio | 4.08 |
|---|---|
| PEG | -4.14 |
| Price to Sales | 2.38 |
| Price to Book Ratio | 0.67 |
| Enterprise Value to Revenue | 2.26 |
| Enterprise Value to EBIT | 3.54 |
| Enterprise Value to Net Income | 2 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
No data
No data available for the latest quarter.
No data available for the latest quarter.
Galapagos N.V. is a fully-integrated biopharmaceutical firm dedicated to discovering, developing, and bringing to market innovative therapies for conditions where patient needs are largely unaddressed. The company boasts a robust pipelin...